(2005) The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: iological and clinical implications (2005) Lupus 14: 931–937ĭe Rycke L, Kruithof E, Van Damme N et al. Clin Rheumatol 22: 56–61ĭe Rycke L, Baeten D, Kruithof E et al. (2003) Anti-TNF-α-induced systemic lupus syndrome. Arthritis Res Ther 7: R545–R551ĭe Bandt M, Vittecoq O, Descamps V et al. Abstact 915ĭe Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X and the Club Rhumatismes et Inflammation (2005) Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: A French national survey. American College of Rheumatology 66 th Annual Meeting, October 25–28, 2002. Arthritis Rheum 43: 2383–2390Ĭhristopher L, Wigley F (2002) TNF-alpha antagonists induce lupus-like syndrome in patients with scleroderma and polyarthritis. (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Rheumatology 40: 1317–1319Ĭharles PJ, Smeenk RT, De Jong J et al. Ann Intern Med 131: 634īleumink GS, Ter Borg EJ, Ramselaar CG, Strickler BHC (2001) Etanercept-induced subacute cutaneous lupus erythematosus. N Engl J Med 348: 601–608īrion PH, Mittal-Henkle A, Kalunian K (1999) Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. Ann N Y Acad Sci 1051: 559–569īaert F, Noman M, Vermeire S et al. (2005) Autoimmunity and anti-TNF-α agents. Arthritis Rheum 50: 3161–3169Ītzeni F, Turiel M, Capsoni F et al. Ann Intern Med 137: 625–626Īringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus.
Ali Y, Sha S (2002) Infliximab-induced systemic lupus erythmatosus.
0 kommentar(er)
